Abstract
Cisplatin, cis-diamminedichloroplatinum(II), and carboplatin, cis-diammine(cyclobutane-1,1-dicarboxylato)platinum(II), are the first drugs from inorganic chemistry to have come under routine clinical use in medical oncology. Their antitumor activity ranges from testicular carcinomas, ovarian carcinomas, and tumors of the head and neck to bladder tumors. However, the spectrum of indication is fairly limited. There is no or only insufficient antitumor activity in tumors which account for the major share of cancer mortality today, e.g. lung tumors and gastrointestinal tumors. Direct derivatives of cisplatin such as carboplatin have only led to a limited reduction or change in drug toxicity. In most cases, the toxicity pattern has changed from nephrotoxicity to myelotoxicity. New metal complexes are now being developed which are designed to supplement the spectrum of indication of platinum complexes. Among non-platinum complexes, budotitane (INN), cis-diethoxybis(1-phenylbutane-1,3-dionato)titanium(IV), is among the most advanced. It is undergoing clinical trials today. Extensive investigations into structure-activity relations have clearly shown a dependence of the activity on the central metal and the diketonato ligand. The tumor-inhibiting effect decreases in the order titanium > zirconium > hafnium > molybdenum > tin > germanium. Antitumor activity is also highly dependent on the nature of the diketonate used. Ligands substituted with planar aromatic ring systems such as the phenyl groups in budotitane are advantageous. Most of the tumor-inhibiting bis(β-diketonato) complexes are cis-configurated. The cis-configurated compounds with an unsymmetrically substituted β-diketonate as ligand are in an equilibrium between three possible cis-isomers in solution at room temperature, due to the fact that the diketonate can rotate via a twist mechanism. The easily hydrolizable group in these complexes does not play a major role in antitumor activity, but it is important for the galenic formulation in the clinic. The ethoxy group as leaving group in budotitane hydrolizes at a slower rate than the corresponding halides.
The best antitumor effects could be obtained with titanium and a diketonato ligand substituted with phenyl groups. Budotitane is highly active in several transplantable tumors and shows promising effects in an autochthonous colorectal tumor model, which is highly predictive for the clinical situation. Side-effects include mild hepatotoxicity and nephrotoxicity. These findings have been confirmed in clinical phase I studies. A phase II study is now in preparation. If preclinical antitumor activity in colorectal tumors can be confirmed in the clinic, this would lead a considerable step forward in the chemotherapy of cancer.
This is a preview of subscription content, log in via an institution.
Preview
Unable to display preview. Download preview PDF.
References
Crooke ST, Mirabelli CK (1983) Am J Med 109: 113
Lewis AJ, Walz DT (1982) In: Ellis GP, West GB (eds) Progress in Medicinal Chem, vol 19, Elsevier Biomedical, New York, p 2
Peyrone M: Annalen der Chemie und Pharmacie, LI, 1 (1844)
Rosenberg B: Interdisciplinary Science Reviews, 3, 2, 134–147 (1978)
Rosenberg B, VanCamp L: Nature, 222, 385–386 (1969)
Knebel N, Schiller Cl.-D, Schneider MR, Schönenberger H, von Angerer E: Eur J Cancer Clin Oncol, 25, 2, 293–299 (1989)
Klenner T, Wingen F, Keppler BK, Krempien B, Schmähl D (1990) J Cancer Res Clin Oncol, 116: 341
Keppler BK, Henn M, Juhl UM, Berger MR, Niebl RE, Wagner FE: Progress in Clin Biochemistry and Medicine, 10, 41–69 (1989)
Alessio E, Mestroni G, Nardin G, Attia WM, Calligaris M, Sava G, Zorzet S: Inorg Chem. 27, 23, 4099–4106 (1988)
Clarke MJ: Metal Ions in Biological Systems, Ed by H Sigel, Vol 11, Metal Complexes as Anticancer Agents, Marcel Dekker, New York, 231–276 (1980)
Ruisi G, Silvestri A, Lo Giudice MT, Barbieri R, Atassi G, Huber F, Grätz K, Lamartina L: J Inorg Biochem 25, 229–245 (1985)
Crowe AJ, Smith PJ, Atassi G: Chem. Biol Interactions, 32, 171–178 (1980)
Gielen M, Willem R, Delmotte A, Joosen E, Meriem A, Melotte M, Vanbellinghen C, Mahieu B, Lelieveld P, de Vos D, Attasi G: Main Group Metal Chemistry, 12, 1, 55–72 (1989)
Berners-Price SJ, Mirabelli CK, Johnson RK, Mattern MR, McCabe FL, Faucette LF, Chiu-Mei Sung, Shau-Ming Mong, Sadler PJ, Crooke ST: Cancer Res., 46, 5486–5493 (1986)
Berners-Price SJ, Sadler PJ: Front Bioinorgan Chem, Xavier, AV (Ed), VCH Publ, Weinheim, FRG, 376–388 (1985 [Publ 1986])
Garzon FT, Berger MR, Keppler BK, Schmähl D: Cancer Chemotherapy and Pharmacology, 19, 347–349 (1987)
Keppler BK, Heim ME: Drugs of the Future, Vol 13, No 5–6, 637–652 (1988)
Heim ME, Keppler BK: Progress in Clin Biochemistry and Medicine, 10, 217–223 (1989)
Köpf-Maier P, Köpf H: Structure and Bonding, 70, 105–181 (1988)
Keller HJ, Keppler BK, Schmähl D: Arzneim.-Forsch./Drug Res, 32 (II), 8, 806–807 (1982)
Keller HJ, Keppler BK, Schmähl D: J Cancer Res Clin Oncol, 105, 109–110 (1983)
Bischoff H, Berger MR, Keppler BK, Schmähl D: J Cancer Res Clin Oncol, 113, 446–450 (1987)
Garzon FT, Berger MR, Keppler BK, Schmähl D: Cancer Letters, 34, 325–330 (1987)
Keppler BK, Michels K: Arzneim: Forsch./Drug Res, 35 (II), 12, 1837–1839 (1985)
Keppler BK, Schmähl D: Arzneim.-Forsch./Drug Res, 36 (II), 12, 1822–1828 (1986)
Keppler BK, Diez A, Seifried V: Arzneim.-Forsch./Drug Res. 35 (II), 12, 1832–1836 (1985)
Keppler BK, Bischoff H, Berger MR, Heim ME, Reznik G, Schmähl D: ISPCC 1987, Padua; Ed by M Nicolini, Proc 5th Int Symp on Platinum and other Metal Coordination Complexes in Cancer Chemotherapy, Martinus Nijhoff Publishing, Boston, 684–694 (1988)
Thompson DW: Structure and Bonding, 9, 27–47 (1971)
Faller JW, Davison A: Inorg Chem, 6, 182 (1967)
Pinnavaia TJ, Fay RC: Inorg Chem, 7, 502 (1968)
Bradley DC, Holloway CE: Chem Comm, 284 (1965)
Wilkie CA, Lin GY, Haworth DT: J Inorg Nucl Chem., 40, 1009 (1978)
Serpone N, Bird PH, Somogyvari A, Bickley DG: Inorg Chem, 16, 9, 2381 (1977)
Jones jr, RW, Fay RC: Inorg Chem, 12, 2599 (1973)
Fay RC, Serpone N: J Am Chem Soc, 90, 5701 (1968)
Lingafelter EC, Braun RL: J Am Chem Soc, 88, 2951 (1966)
Collman JP: Angew Chem, 77, 154 (1966)
Calvin M, Wilson KW: J Am Chem Soc, 67, 2003 (1945)
Martell RE, Calvin M: Die Chemie der Metallverbindungen Verlag Chemie Weinheim (1958)
Bayer E: Angew Chem, 3, 325 (1964)
Bayer E: Angew Chem, 76, 76 (1964)
Collman JP, Moss RA, Maltz H, Heindel CC: J Am Chem Soc, 83, 531 (1961)
Kluiber RW: J Am Chem Soc, 82, 4839 (1960)
Kluiber RW: J Am Chem Soc, 83, 3030 (1961)
Collman JP, Marshall RL, Young (III) WL, Sears jr CT: J Org Chem., 28, 1449 (1963)
Collman JP, Marshall RL, Young WL, Goldby SD: Inorg Chem 1, 704 (1962)
Barker RH, Collman JP, Marshall RL: J Org Chem., 29, 3216 (1964)
Djoidjeric L, Lewis J, Nyholm RS: Chem Ind., 122 (1959)
Bock B, Flatau K, Junge H, Kuhr M, Musso H: Angew Chem, 7, 83, Jahrg, 239–249 (1971)
Hon P.-H, Belford RL, Pfluger CE: Inorg Chem., 5, 516 (1966)
Bradley DC, Holloway CE: J Chem Soc (A), 282 (1969)
Serpone N, Fay RC: Inorg Chem., 8, 11, 2379 (1969)
Krüger U, Kukat B, Keppler BK: - unpublished results
Smith GD, Caughlan CN, Campbell JA: Inorg Chem 11, 2989 (1972)
Keppler BK, Berger MR, Klenner T, Heim ME: Advances in Drug Research, 19, 243–310 (1990)
Keppler BK, Heim ME, Flechtner H, Wingen F, Pool B: Arzneim.-Forsch./Drug Res, 39 (I), 6, 706–709 (1989)
Heim ME, Flechtner H, Keppler BK, Queißer W: Contrib Oncol, 37, Queißer, W., Fiebig, HH (Eds) Karger, Basel, 168–175 (1989)
Keppler BK: Nachr Chem Tech Lab, 35, 10, 1029–1036 (1987)
Author information
Authors and Affiliations
Rights and permissions
Copyright information
© 1991 Springer-Verlag
About this chapter
Cite this chapter
Keppler, B.K., Friesen, C., Moritz, H.G., Vongerichten, H., Vogel, E. (1991). Tumor-inhibiting bis(β-Diketonato) metal complexes. Budotitane, cis-diethoxybis(1-phenylbutane-1,3-dionato)titanium(IV). In: Bioinorganic Chemistry. Structure and Bonding, vol 78. Springer, Berlin, Heidelberg. https://doi.org/10.1007/3-540-54261-2_2
Download citation
DOI: https://doi.org/10.1007/3-540-54261-2_2
Published:
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-540-54261-2
Online ISBN: 978-3-540-47535-4
eBook Packages: Springer Book Archive